Diabetic Kidney Disease (Diabetic Nephropathy)

5 mg once daily initially (2.5 mg once daily if CrCl <=30 mL/min), titrate up to maximum 40 mg once daily as tolerated - long-term

Specialist pediatric endocrinology/nephrology management

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD, Figure 3

Titrate to the highest dose the patient tolerates - the albuminuria benefit is dose-dependent. Give it with the SGLT2 inhibitor, not instead of one.

50 mg once daily, titrate to 100 mg once daily if enalapril is not tolerated due to ACEi cough - long-term

Specialist pediatric use only

KDIGO Clinical Practice Guideline for Diabetes Management in CKD 2022

Replaces enalapril when the cough will not settle. Never both - an ACE inhibitor and an ARB together raise potassium and creatinine without adding benefit. The empagliflozin continues either way.

150 mg once daily, increased if tolerated to 300 mg once daily. Start at 75-150 mg once daily in patients aged 75 and over or on haemodialysis - Long-term

Efficacy and safety in children have not been established.

Sourced preference. The Egyptian formulary carries an irbesartan indication that reads as this condition word for word, and 23 products stock it.

Egyptian National Drug Formulary - Cardiovascular 2024 (irbesartan monograph)

23 live products, and the formulary carries an indication that is this condition word for word - 'renal disease in hypertensive type 2 diabetes mellitus' - with its own dose. It is the best-evidenced ARB for diabetic nephropathy specifically.

10 mg once daily in the morning - long-term

Not approved under 10 years; specialist management age >=10

KDIGO Clinical Practice Guideline for Diabetes Management in CKD 2022

Foundational therapy in its own right, not an optional extra. It slows the decline in eGFR by a mechanism the ACE inhibitor does not share, so the two are given together.

500 mg once or twice daily with meals to start, titrated by 500 mg every 7 days to a usual maintenance of 1000 mg twice daily; maximum 2550 mg/day. Halve the dose if eGFR is 30-44; stop below 30 - long-term

Specialist paediatric endocrinology. Diabetic kidney disease is not a primary-care paediatric condition.

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, Recommendation 4.1.1 and Figures 26 and 27

Metformin is KDIGO's first-line glucose-lowering drug down to eGFR 30, and the eGFR thresholds are the reason it belongs on the diabetic kidney disease card rather than only on the type-2-diabetes card. The SGLT2 inhibitor here is given by KDIGO for kidney protection rather than for glucose.

Chronic Kidney Disease - disease-level clinical article (diabetic-kidney-disease-clinical.txt)

Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.

10 mg once daily if eGFR is 25-59 mL/min/1.73m2, or 20 mg once daily if eGFR is 60 or above; uptitrate from 10 mg to 20 mg after 4 weeks if serum potassium is 4.8 mmol/L or less - long-term

Not established in children.

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, Practice Point 1.4.4

The third pillar of KDIGO's regimen, and it is added on top of the ACE inhibitor and the SGLT2 inhibitor, not instead of either. Practice Point 1.4.2 states a nonsteroidal MRA can be added to a RASi and an SGLT2i. Two brands are marketed in Egypt.

20 mg once daily for primary prevention, increased if needed; 80 mg once daily if there is established cardiovascular disease - long-term

The formulary's paediatric atorvastatin dose from 10 years is for familial hypercholesterolaemia, a different indication. Diabetic kidney disease is not a paediatric primary-care condition.

Egyptian National Drug Formulary - Cardiovascular 2024 (atorvastatin monograph)

KDIGO puts a moderate- or high-intensity statin in the first-line drug therapy box of its own management figure for every patient with diabetes and CKD. The patient in front of you is far more likely to die of a myocardial infarction than to reach dialysis, and the statin is the drug that addresses that.